Respiratory News and Research

RSS

Impact of COVID-19 on mental health in the US: CDC report

The study, published in CDC's Morbidity and Mortality Weekly Report (MMWR), underlies the importance of evaluating the impact of strategies addressing adult mental health status during the pandemic. This way, these can help plan strategies and interventions for the affected groups.

30 Mar 2021

mRNA COVID-19 vaccines are highly effective among front liners, CDC study shows

The study, published in CDC's Morbidity and Mortality Weekly Report (MMWR), highlights the efficacy of mRNA vaccines in protecting against SARS-CoV-2 infection.

30 Mar 2021

SARS-CoV-2 mutation T478K spreading at alarming speed in Mexico

Several SARS-CoV-2 variants have emerged, posing a renewed threat to COVID-19 containment and to vaccine and drug efficacy. In this study, we analyzed more than 820,000 SARS-CoV-2 genomic sequences deposited up to March 26, 2021 and identified a novel T478K mutation located on the SARS-CoV-2 Spike protein.

30 Mar 2021

Comparing the transmission routes of two SARS-CoV-2 variants of concern

The research team had previously identified the UK variant as having higher viral RNA shedding than the D614G variant. However here, they wanted to compare the transmission of such variants through different routes of potential infection: direct contact, aerosol (airborne droplets), and fomite (objects which may be contaminated and therefore spread infectious agents).

30 Mar 2021

Microbiota-derived molecules do not change the entry or replication of SARS-CoV-2 in intestinal cells

A study conducted at the University of Campinas in the state of São Paulo, Brazil, shows that compounds produced by gut microbiota (bacteria and other microorganisms) during fermentation of insoluble fiber from dietary plant matter do not affect the ability of the novel coronavirus SARS-CoV-2 to enter and replicate in cells lining the intestines.

30 Mar 2021

Researchers examine the evolutionary race between SARS-CoV-2 and human defenses

Researchers have analyzed this evolution of the virus based on evolutionary ecology theory. Using the virus genomes available in the Global Initiative on Sharing Avian Influenza Data (GISAID) database, the researchers focused their inquiry on mutations in the receptor-binding domain (RBD) on the spike protein of SARS-CoV-2.

30 Mar 2021

Researchers develop novel test that screens for SARS-CoV-2 variants of concern

A team of scientists from the United States has recently developed a single-tube duplex molecular assay for rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants containing E484K and N501Y spike mutations.

30 Mar 2021

Single dose of Pfizer and Oxford vaccines shows 60% efficacy in elderly care home residents

A new study deals with the effect of two widely used vaccines in eliciting humoral immunity against the virus in this group. These are the Oxford/AstraZeneca viral-vectored vaccine (ChAdOx1 nCoV-19), and the Pfizer/BioNTech’s messenger RNA-based vaccine (BNT162b2). Both express the viral spike antigen, and both are currently being employed in the UK’s vaccination program.

30 Mar 2021

Study finds rapid increase in IgG and IgA antibody levels following COVID-19 mRNA vaccination

A new study describes the kinetics of the antibody response to the earliest approved vaccines against COVID-19, which were developed on an mRNA platform.

30 Mar 2021

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

In the continued need for next-generation vaccines that confer broad protection against COVID-19, scientists developed an adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine.

30 Mar 2021

Determination of vaccine-elicited SARS-CoV-2 antibodies in breastmilk

A new study has analyzed the levels of SARS-CoV-2 antibodies elicited by the novel COVID-19 vaccines in breastmilk.

30 Mar 2021

More people now willing to get vaccinated against SARS-CoV-2, study finds

The study, which appeared on the pre-print server medRxiv, aimed to examine the general public's willingness to receive COVID-19 vaccines and their safety concerns.

30 Mar 2021

Scientists develop new method to estimate prevalence of SARS-CoV-2 antibodies

In the study, which appeared on the pre-print server medRxiv*, the team also modeled the pandemic phases with exponential growth and decay. The model improves upon maximum likelihood estimates by conditioning on more data.

30 Mar 2021

Nanoparticles elicit neutralizing antibodies to diverse SARS-CoV-2 variants

Spike-protein-based nanoparticle vaccine candidates were retained longer in follicular dendritic cells and showed higher germinal center reactions in lymph node follicles compared to soluble spike protein vaccine.

30 Mar 2021

Using ACE2 structure to predict SARS-CoV-2 susceptibility in animals

Researchers based at the Rice University, Texas, USA, have now demonstrated a novel method of predicting a species' susceptibility to contracting COVID-19, based on the animal's structure of ACE2.

30 Mar 2021

Scientists study the sensitivity of SARS-CoV-2 variants to neutralize antibodies

The B.1.1.7 and B.1.351 variants of SARS-CoV-2 were first detected in the UK and South Africa respectively, and have since spread to many other countries.

29 Mar 2021

Arginine methylation important in SARS-CoV-2 viral replication

Researchers show that methylation of arginine in the virus nucleocapsid protein controls the protein's functions and plays a role in the life cycle of the SARS-CoV-2 virus.

29 Mar 2021

Vaccine-induced 2C08 antibody protects against SARS-CoV-2 variants

A new preprint study posted to the bioRxiv* server led by Ali H. Ellebedy from the Washington University School of Medicine found that the monoclonal antibody 2C08 produced by the Pfizer vaccine could help neutralize COVID-19 variants.

29 Mar 2021

Have scientists found SARS-CoV-2's Achilles' heel?

Have scientists uncovered the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Achille's heel? New preclinical research from Cell neutralizing antibodies targeting the N-terminal domain of the coronavirus could be a potential target for antibodies to bind and effectively neutralize SARS-CoV-2.

29 Mar 2021

New study reports increased spread of B.1.1.7 variant in Houston, Texas

Research led by Jimmy Gollihar from the CCDC Army Research Laboratory-South in Austin, Texas found the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 —first detected last fall in England — increased in Houston, Texas. The B.1.1.7 variant is rapidly spreading with a case doubling time of 6.9 days.

29 Mar 2021